Lodonal and HIV / AIDS

Fierce pharma writes about UCSF tackling HIV. They are making strides and we hope we can treat all people with HIV/AIDS soon! "A team at the University of California in San Francisco has brought a large-scale version of CRISPRgene editing to the fight against HIV infection, offering possibilities for both the discovery of new techniques and the ability to treat those with the virus. The researchers at UCSF developed a high-throughput CRISPR platform to modify the genes in immune cells to defend them against HIV. As they test different editing methods, they hope to home in on the combination that will protect the donated cells."

In line with other studies that showed a positive effect of LodonalTM in HIV+ patients, this 90- day trial once again solidifies the therapeutic role LodonalTM can have on HIV+ patients.The shorter duration of this study demonstrated that even within limited time frame, LodonalTM’s effects can be felt qualitatively and observed clinically. The lack of abnormal liver function means that the drug was well tolerated in the local population and the positive effects of LodonalTM in the first 30 days sustained after 30 days. Our results also seem to indicate that patients with lower CD4 count may fair better with LodonalTM than patients with values above 500. An increase in CD4 count would have a stabilizing effect on the immune system, thus reducing the chances of opportunistic infections and prolong life in patients with HIV.

  The objective of showing the more than 25% increase CD4 count and percentage in the Treatment group between Day-1 and Day-90 was demonstrated, whilst the Placebo group only demonstrated an average of 11% increase. 

The objective of showing the more than 25% increase CD4 count and percentage in the Treatment group between Day-1 and Day-90 was demonstrated, whilst the Placebo group only demonstrated an average of 11% increase.